Product logins

Find logins to all Clarivate products below.


chevron_left

Companies to Watch: Next Generation Gene Editing

What’s next for the field of gene editing
Startups, targets and indications driving the next generation of gene editing therapeutics

The FDA’s late-2023 approval of Casgevy™ and Lyfgenia™ for the treatment of sickle cell disease and beta thalassemia was a watershed event ushering in the age of gene editing therapeutics. What’s next for this burgeoning field of medical science?

Companies to Watch: Gene Editing will explore:

  • As-yet under-the-radar startups, and the targets and indications they are probing
  • Clinical, regulatory, market access and IP challenges that would-be entrants to the space must navigate
  • The potential impact of these therapeutics on regulators, payers, clinicians and patients

 

 

Related insights

The latest news, technologies, and resources from our team.

Mosaic Health: Elevance Health’s bold move to transform primary-care delivery Mosaic Health: Elevance Health’s bold move to transform primary-care delivery
Mosaic Health: Elevance Health’s bold move to transform primary-care delivery
ISPOR Europe 2024 ISPOR Europe 2024
ISPOR Europe 2024
United States Peripheral Bioresorbable Stent United States Peripheral Bioresorbable Stent
United States Peripheral Bioresorbable Stent
chevron_left
chevron_right